Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary aldosteronism in general practice
NL-OMON37681Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of spironolactone and eplerenone in primary aldosteronism (PA) and hypertension (HTN) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Prevalence of primary aldosteronism, Composite cardiorenovascular damage difference and 1 more. Started Aug 2013; status: recruiting.
02
Drugs
spironolactoneeplerenone
03
Conditions
primary aldosteronism (PA)hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON37681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37681.